Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

On Tues 6 June 2017, researchers vaccinated volunteers and began Mahidol University’s study of the malaria vaccine RTS,S/AS01. This is the first study in Asia of the vaccine, an advanced product that has received regulatory approval in Europe.

On Tues 6 June, researchers vaccinated volunteers and began Mahidol University’s study of the malaria vaccine RTS,S/AS01. This is the first study in Asia of the vaccine, an advanced product that has received regulatory approval in Europe.

Several extensive clinical trials of RTS,S/AS01 have previously been conducted in children in sub-Saharan Africa. In a large Phase 3 trial of RTS,S/AS01E at 11 sites in seven sub-Saharan African countries, efficacy against clinical malaria in children aged 5–17 months following three primary doses was 45.1% (CI 41.4 to 48.7), 35.2% (CI 30.5 to 39.5) and 28.3% (CI 23.3 to 32.9) during 20, 32 and 48 months of follow-up, respectively.

Profs. Sasithon (3rd left), Nick White (centre) and colleagues show their delight that Mahidol’s RTS,S/AS01 vaccine study has started. Right: The RTS,S/AS01 vaccine and adjuvant.

While such a “leaky” vaccine is not ideal in high transmission settings, it could be useful in combination with other interventions such as mass drug administrations in the elimination of malaria in the Greater Mekong Subregion, leading malaria researchers say.

“RTS,S is the most advanced of the malaria vaccine candidates. This is the first time the vaccine is evaluated in an Asian population. If found to be safe and effective, RTS,S could be the urgently needed tool to expedite the elimination of malaria in the Greater Mekong Subregion,” said Dr Lorenz von Seidlein, Coordinator of MORU’s TME programme.

Expected to last 6 months, the Mahidol study will recruit 190 health adult volunteers to explore the immunogenicity and safety of various vaccine regimens with and without antimalarial drugs.

Funded by the Malaria Vaccine Initiative/PATH, the study is supervised by Mahidol Prof Sasithon Pukrittayakamee, Dr Borimas Hanboonkunupakarn and Dr Podjanee Jittamala and is coordinated by Pongphaya Pongsuwan. MORU investigators Sir Nick White, Nick Day, Arjen Dondorp and Lorenz von Seidlein will support the study implementation.

Similar stories

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

MORU Bangkok Publication Research

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

Susie Dunachie awarded flagship NIHR career development award

Awards & Appointments MORU Bangkok

Susie Dunachie joins a prestigious group of leading health researchers in the latest cohort of NIHR Global Research Professors. These awards fund research leaders of the future to promote effective translation of research and to strengthen health, public health and care research leadership at the highest academic levels. Research conducted by Global Research Professors directly benefits people in LMICs. A Consultant in Infectious Diseases and Medical Microbiology, Susie works on the development of a vaccine to prevent death from melioidosis in people with type 2 diabetes mellitus in LMICs, and supports vaccine research in Thailand. Congratulations!

The COVID-19 vaccine: do we know enough to end the pandemic?

MORU Bangkok Research

Blog by Rima Shretta. Preliminary efficacy results from three vaccine candidates currently in Phase 3 trials have shown an efficacy of more than 90% against the development of symptomatic COVID-19. While these results are promising, all vaccines are in relatively early stages of testing. A comprehensive and transparent roadmap is urgently needed, to determine how limited doses of the first vaccines to be licensed will be distributed, together with which groups will initially be prioritized.

New study on the risk of Plasmodium vivax parasitaemia after Plasmodium falciparum malaria

MORU Bangkok Publication Research

A new study quantifying the high risk of Plasmodium vivax parasitaemia after treatment of Plasmodium falciparum malaria aims to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy with a hypnozoitocidal antimalarial drug, would be most beneficial.

Applicability of COVID-19 vaccine trial results to low-and-middle-income countries

COVID-19 MORU Bangkok

In the next few months, the first Phase 3 COVID-19 vaccine trials – the majority of them in upper-middle or high-income countries and in specific target populations like young adults – will report their results. How relevant will their study results be for low-resource settings?

Congratulations new NDM professors

Awards & Appointments LOMWRU MORU Bangkok

The University of Oxford has awarded CTMGH two new Professors. Elisabeth Ashley - UK-trained physician who specialises in infectious diseases and medical microbiology & virology, and Director of the Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU) in Lao PDR since 2019, Liz is conferred the title of Professor of Tropical Medicine. Stuart Blacksell - Senior Research Scientist based at the Mahidol-Oxford Tropical Medicine Research Unit (MORU) in Thailand, Stuart is conferred the title of Professor of Tropical Microbiology.